Wave Life Sciences is a technology company.
Wave Life Sciences has raised $84.0M across 2 funding rounds.
Wave Life Sciences has raised $84.0M in total across 2 funding rounds.
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company developing RNA-based therapies for devastating diseases, using its proprietary PRISM platform to design stereopure oligonucleotides that repair, restore, or reduce proteins.[1][2] It targets genetically defined conditions, including rare and prevalent disorders like Huntington's disease (HD), through modalities such as RNA editing, splicing, and silencing via RNAi or antisense mechanisms, serving patients with high unmet needs in neurology and beyond.[1][2][3]
The company solves challenges in traditional oligonucleotide therapies by producing stereopure compounds that enhance potency, specificity, distribution, and durability, enabling allele-specific approaches for mutations like those in HD.[2][3] Wave demonstrates growth momentum as a publicly traded biotech since 2015, advancing the first RNA editing program into clinical trials and building a neurology franchise.[2][3]
Founded before its 2015 public listing, Wave Life Sciences emerged from innovations in oligonucleotide chemistry, challenging conventions to create stereopure nucleic acids for untreatable genetic diseases.[3] Headquartered in Cambridge, MA, the company started with a focus on precision medicine, particularly in neurology, recognizing HD's mutation as an ideal target for its platform's allele-specific capabilities.[3]
Early traction came from its proprietary synthesis technology, which eliminates complex stereoisomer mixtures to control pharmacology and reduce side effects, setting the stage for broader applications like exon skipping.[3] Key leaders, including experts in clinical operations, patient advocacy, and neurology, drove initial efforts in HD and expanded the platform's versatility.[3]
Wave rides the wave of RNA therapeutics advancement, harnessing cellular machinery for protein modulation amid rising demand for precision genetic medicines beyond CRISPR gene editing.[2] Timing aligns with maturing oligonucleotide tech, where chemistry breakthroughs like stereopurity address past limitations in efficacy and safety, fueled by market forces like aging populations and orphan disease incentives.[2][3]
It influences the ecosystem by proving versatile platforms can tackle both rare (e.g., HD) and common disorders, inspiring biotechs to prioritize RNA editing and splicing while contributing to Massachusetts' biotech hub.[1][3]
Wave is poised to expand clinical pipelines, with RNA editing programs potentially yielding first approvals and validating PRISM across modalities.[2] Trends like AI-driven genetics and multi-modality combos will accelerate its breakthroughs, evolving its role from neurology pioneer to RNA medicines leader for diverse diseases.[1][2] This positions Wave to transform patient futures, fulfilling its mission for life-changing therapies from the start.[1]
Wave Life Sciences has raised $84.0M in total across 2 funding rounds.
Wave Life Sciences's investors include RA Capital.
Wave Life Sciences has raised $84.0M across 2 funding rounds. Most recently, it raised $66.0M Series B in August 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2015 | $66.0M Series B | RA Capital | |
| Feb 1, 2015 | $18.0M Series A | RA Capital |